Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently considered as the standard therapy for patients with advanced non-small cell lung cancer (NSCLC) who have EGFR-activating mutations. However, despite an initially profound response to these drugs, these patients ul...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Cheng, Wang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719261/
https://www.ncbi.nlm.nih.gov/pubmed/34987800
http://dx.doi.org/10.3892/mco.2021.2463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719261/
https://www.ncbi.nlm.nih.gov/pubmed/34987800
http://dx.doi.org/10.3892/mco.2021.2463

Ejemplares similares